A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
ITEM 1. BUSINESS. (a) Business Development As used in this Annual Report on Form 10-K, or the Annual Report, references to the “Company”, “we”, “us”, or “our” refer to BioRestorative Therapies, Inc. We were incorporated in Nevada on June 13, 1997. On August 15, 2011, we changed our name from “Stem Cell Assurance, Inc.” to “BioRestorative Therapies, Inc.” Effective January 1, 2015, we reincorporated in Delaware. Effective December 31, 2022, we reincorporated in Nevada. We develop therapeutic products using cell and tissue protocols, primarily involving adult stem cells. We are currently pursuing our Disc/Spine Program with our initial investigational therapeutic product being called BRTX-100. In March 2022, a United States patent issued in our Disc/Spine Program. We submitted an investigational new drug, or IND, application to the U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 383K | - | - | - | - | 77K |
| Net Income | -13M | -9.0M | -10M | -13M | -44M | - |
| EPS | $-1.46 | $-1.16 | $-2.47 | $-3.65 | $-37.30 | $-114,240.00 |
| Free Cash Flow | -11M | -8.3M | -6.6M | -6.2M | -3.4M | -2.0M |
| ROIC | -203.2% | -107.0% | -104.1% | -124.0% | -92.6% | - |
| Gross Margin | 93.3% | - | - | - | - | - |
| Debt/Equity | 0.00 | 0.44 | 0.02 | 0.03 | 0.07 | -5.76 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -15M | -12M | -15M | -19M | -26M | -2.8M |
| Operating Margin | -3785.1% | - | - | - | - | -3574.1% |
| ROE | -574.1% | -96.9% | -104.1% | -125.5% | -937.5% | - |
| Shares Outstanding | 9M | 8M | 4M | 4M | 4M | 0M |
BioRestorative Therapies, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
BioRestorative Therapies, Inc. (BRTX) has a 5-year average return on invested capital (ROIC) of -106.9%. This is below average and may indicate limited pricing power.
BioRestorative Therapies, Inc. (BRTX) has a market capitalization of $2M. It is classified as a small-cap stock.
BioRestorative Therapies, Inc. (BRTX) does not currently pay a regular dividend.
BioRestorative Therapies, Inc. (BRTX) operates in the Services-Misc Health & Allied Services, Nec industry, within the Healthcare sector.
BioRestorative Therapies, Inc. (BRTX) generated $-8 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
BioRestorative Therapies, Inc. (BRTX) has a debt-to-equity ratio of 0.44. This indicates a conservatively financed balance sheet.
BioRestorative Therapies, Inc. (BRTX) reported earnings per share (EPS) of $-1.16 in its most recent fiscal year.
BioRestorative Therapies, Inc. (BRTX) has a return on equity (ROE) of -96.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 14 years of financial data for BioRestorative Therapies, Inc. (BRTX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
BioRestorative Therapies, Inc. (BRTX) has a book value per share of $1.10, based on its most recent annual SEC filing.